리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 12월
페이지 정보:영문 223 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 성장인자(혈액 및 조직 유래) 시장은 2030년까지 1,015억 달러에 달할 전망
성장인자(혈액 및 조직 유래) 세계 시장은 2024년에 622억 달러로 추정되며, 2024년부터 2030년까지의 분석 기간 동안 CAGR 8.5%로 성장하여 2030년까지 1,015억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석 대상이 된 부문 중 하나인 인터페론은 10.1%의 CAGR을 기록하며 분석 기간 종료시까지 782억 달러에 달할 것으로 예측됩니다. 집락자극인자 부문의 성장률은 분석 기간 동안―1.4%의 CAGR로 추정됩니다.
미국 시장은 160억 달러로 추정되는 한편 중국은 13.0%의 CAGR로 성장할 것으로 예측됩니다
미국 성장인자(혈액 및 조직) 시장은 2024년에 160억 달러로 추정됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2024년부터 2030년까지의 분석 기간 동안 CAGR 13.0%를 기록하며 2030년까지 262억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다가 있으며, 각각 분석 기간 동안에 CAGR 4.1%, 7.7%로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 5.2%의 CAGR로 성장할 것으로 예측됩니다.
세계의 성장인자(혈액 및 조직) 시장 - 주요 시장 동향과 촉진요인 개요
성장인자란 무엇인가? 의료 발전에서 왜 중요한가?
성장인자는 세포의 증식, 분화, 조직 복구 등 다양한 세포 과정을 조절하는 데 매우 중요한 역할을 하는 천연 유래 단백질 또는 호르몬입니다. 이러한 생물학적 분자는 손상이나 질병에 대한 신체의 반응에 필수적이며, 손상된 조직의 회복과 재생을 촉진합니다. 상피성장인자(EGF), 섬유아세포성장인자(FGF), 혈관내피성장인자(VEGF) 등의 성장인자는 그 치료적 잠재력에 대해 널리 연구되고 있습니다. 임상 현장에서는 상처 치유 촉진, 이식 조직 성장 지원, 재생의료 시술의 성과 향상에 성장인자가 활용되고 있습니다. 이러한 인자가 체내의 회복 메커니즘을 자극하는 능력은 만성 상처와 화상, 심혈관질환, 정형외과적 손상 등 다양한 질환을 치료하는 데 매우 유용합니다.
기술 혁신은 의료 분야의 성장 인자 활용을 어떻게 촉진하고 있는가?
기술 발전은 성장인자의 의료 응용을 크게 촉진하고 치료 가능성과 효능을 확장하고 있습니다. 최근 생명공학 및 유전공학의 혁신으로 재조합 성장인자의 대규모 생산이 가능해져 보다 쉽게 접근 가능하고 비용 효율적일 수 있게 되었습니다. 또한, 나노입자, 하이드로겔 등 첨단 전달 시스템의 개발로 성장인자의 손상 부위로의 표적 전달과 지속적 방출이 개선되어 치료 효과가 향상되고 있습니다. 조직공학 및 재생의료 분야에서도 성장인자가 스캐폴드 및 생체재료에 내장되어 조직 재생 및 복구를 촉진하는 등 이러한 발전의 혜택을 누리고 있습니다. 이러한 기술적 진보는 성장인자의 효능을 높일 뿐만 아니라 복잡한 의료 시술 및 치료에 대한 적용 가능성도 새롭게 열어주고 있습니다.
다양한 의료 분야에서 성장인자 수요가 급증하는 이유는 무엇일까?
성장인자의 치료적 이점이 널리 알려지면서 다양한 의료 분야에서 그 수요가 급증하고 있습니다. 피부과 영역에서는 피부 회춘을 촉진하고 노화의 징후를 완화하기 위해 미용 시술에 성장인자를 사용합니다. 정형외과 분야에서는 골절 및 연부조직 손상의 치유를 가속화하는 데 중요한 역할을 하고 있습니다. 심혈관 분야에서도 허혈성 질환 환자의 혈관신생 촉진 및 혈류 개선을 위해 성장인자가 활용되고 있습니다. 또한, 재생의료 분야에서는 줄기세포배양 및 이식용 바이오 엔지니어링 조직 개발에 필수적인 존재입니다. 이러한 다양한 의료 영역에서의 성장인자 적용 확대는 현대 의학에서 성장인자의 중요성을 입증하는 동시에 그 잠재력을 극대화하기 위한 연구개발의 지속적인 추진으로 이어지고 있습니다.
성장 인자 시장의 성장을 이끄는 요인은 무엇일까?
성장 인자 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 생명공학 및 유전공학의 기술적 진보로 인해 재조합 성장인자의 생산 효율성과 비용 효율성이 향상되어 공급량이 증가하고 있습니다. 당뇨병, 심혈관질환 등 조직 복구 및 재생을 필요로 하는 만성질환의 유병률 증가가 성장인자에 대한 수요를 촉진하고 있습니다. 또한, 성장 인자에 크게 의존하는 재생의료 및 조직공학 접근법의 채택 확대가 시장 성장을 촉진하고 있습니다. 피부 회춘과 상처 치유에 성장인자를 이용한 미용 및 피부과 치료의 증가도 시장을 더욱 확대시키고 있습니다. 또한, 성장인자의 효능과 표적 지향성을 높이는 혁신적인 약물전달 시스템의 개발은 많은 투자를 유치하여 시장 확대를 촉진하고 있습니다. 첨단 치료 용도에 대한 정부 자금 지원과 지원적인 규제 프레임워크도 성장인자 시장의 성장을 견인하는 데 중요한 역할을 하고 있습니다.
부문:
성장인자(인터페론, 콜로니자극인자, 에리트로포이에틴, 인터류킨, 기타 성장인자)
조사 대상 기업 예시
Amgen, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biocon Ltd.
Biogen, Inc.
Biopharm GmbH
Bolder BioTechnology, Inc.
Chugai Pharmaceutical Co. Ltd.
F. Hoffmann-La Roche AG
FibroGen, Inc.
Genentech, Inc.
Janssen Biotech, Inc.
Johnson & Johnson
Lonza Group
Merck Serono
PeproTech, Inc.
Reliance GeneMedix Plc
Sangamo Therapeutics, Inc.
Sanofi
Scil Proteins GmbH
Teva Pharmaceutical Industries Ltd.
Wockhardt Ltd.
AI 통합
검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보를 혁신하고 있습니다.
Market Glass, Inc.는 LLM이나 산업 특화형 SLM을 쿼리하는 일반적인 방식이 아닌, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 동영상 전사, 블로그, 검색 엔진 조사, 그리고 방대한 양의 기업 데이터, 제품/서비스 데이터, 시장 데이터 등이 포함됩니다.
관세 영향 계수
Market Glass, Inc.가 본사 소재지, 생산기지, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁 변화를 예측하면서 지리적 시장에 대한 관세의 영향을 반영하였습니다. 이러한 복잡하고 다면적인 시장 현실은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 경쟁사에게 다양한 영향을 미치며, 미시적 및 거시적 시장 역학에도 영향을 미칩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Growth Factors (Blood and Tissue) Market to Reach US$101.5 Billion by 2030
The global market for Growth Factors (Blood and Tissue) estimated at US$62.2 Billion in the year 2024, is expected to reach US$101.5 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Interferons, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$78.2 Billion by the end of the analysis period. Growth in the Colony Stimulating Factors segment is estimated at -1.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$16.0 Billion While China is Forecast to Grow at 13.0% CAGR
The Growth Factors (Blood and Tissue) market in the U.S. is estimated at US$16.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$26.2 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.
Global Growth Factors (Blood and Tissue) Market - Key Trends and Drivers Summarized
What Are Growth Factors and Why Are They Crucial for Medical Advancements?
Growth factors are naturally occurring proteins or hormones that play a pivotal role in regulating various cellular processes, including cell proliferation, differentiation, and tissue repair. These biological molecules are critical in the body's response to injury and disease, facilitating the repair and regeneration of damaged tissues. Growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) are extensively studied for their therapeutic potential. In clinical settings, growth factors are utilized to enhance wound healing, support the growth of grafted tissues, and improve the outcomes of regenerative medicine procedures. The ability of these factors to stimulate the body's intrinsic repair mechanisms makes them invaluable in treating a wide range of medical conditions, from chronic wounds and burns to cardiovascular diseases and orthopedic injuries.
How Are Technological Innovations Enhancing the Use of Growth Factors in Medicine?
Technological advancements are significantly boosting the application of growth factors in medicine, expanding their therapeutic potential and efficacy. Recent innovations in biotechnology and genetic engineering have enabled the large-scale production of recombinant growth factors, making them more accessible and cost-effective. Additionally, the development of advanced delivery systems, such as nanoparticles and hydrogels, has improved the targeted delivery and sustained release of growth factors at the injury site, enhancing their therapeutic impact. Tissue engineering and regenerative medicine have also benefited from these advancements, with growth factors being incorporated into scaffolds and biomaterials to promote tissue regeneration and repair. These technological strides not only enhance the effectiveness of growth factors but also open up new possibilities for their application in complex medical procedures and treatments.
Why Is There a Surge in Demand for Growth Factors in Various Medical Fields?
The increasing recognition of the therapeutic benefits of growth factors has led to a surge in their demand across various medical fields. In dermatology, growth factors are used in cosmetic procedures to stimulate skin rejuvenation and reduce signs of aging. In orthopedics, they play a crucial role in accelerating the healing of bone fractures and soft tissue injuries. The cardiovascular field also leverages growth factors to promote angiogenesis and improve blood flow in patients with ischemic conditions. Moreover, growth factors are integral to the field of regenerative medicine, where they are used to cultivate stem cells and develop bioengineered tissues for transplantation. The expanding application of growth factors in these diverse medical domains underscores their importance in modern healthcare and drives continuous research and development efforts to explore their full potential.
What Factors Are Driving the Growth in the Growth Factors Market?
The growth in the growth factors market is driven by several factors. Technological advancements in biotechnology and genetic engineering are making the production of recombinant growth factors more efficient and cost-effective, thereby increasing their availability. The rising prevalence of chronic diseases and conditions that require tissue repair and regeneration, such as diabetes and cardiovascular diseases, is spurring demand for growth factors. Additionally, the increasing adoption of regenerative medicine and tissue engineering approaches, which rely heavily on growth factors, is propelling market growth. The growing number of cosmetic and dermatological procedures that utilize growth factors for skin rejuvenation and wound healing further expands the market. Moreover, the development of innovative drug delivery systems that enhance the efficacy and targeted action of growth factors is attracting significant investments and fostering market expansion. Government funding and supportive regulatory frameworks for advanced therapeutic applications also play a crucial role in driving the growth of the growth factors market.
SCOPE OF STUDY:
The report analyzes the Growth Factors (Blood and Tissue) market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 101 Featured) -
Amgen, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biocon Ltd.
Biogen, Inc.
Biopharm GmbH
Bolder BioTechnology, Inc.
Chugai Pharmaceutical Co. Ltd.
F. Hoffmann-La Roche AG
FibroGen, Inc.
Genentech, Inc.
Janssen Biotech, Inc.
Johnson & Johnson
Lonza Group
Merck Serono
PeproTech, Inc.
Reliance GeneMedix Plc
Sangamo Therapeutics, Inc.
Sanofi
Scil Proteins GmbH
Teva Pharmaceutical Industries Ltd.
Wockhardt Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
Global Economic Update
Growth Factors (Blood and Tissue) - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Chronic Diseases Spurs Demand for Growth Factors
Rise in Regenerative Medicine Expands Addressable Market Opportunity
Innovations in Drug Delivery Systems Strengthen Business Case for Growth Factors
Advancements in Biotechnology Propel Growth in Growth Factors Market
Growing Adoption of Tissue Engineering Generates Demand for Growth Factors
Integration of Growth Factors in Orthopedic Treatments Propels Market Expansion
Increasing Application of Growth Factors in Cardiovascular Therapies
Advances in Genetic Engineering Accelerate Demand for Recombinant Growth Factors
Expansion of Stem Cell Research Throws the Spotlight on Growth Factors
Technological Innovations in Biomaterials Propel Growth in the Use of Growth Factors
Rising Demand for Growth Factors in Wound Healing and Burn Treatment Expands Market Scope
Impact of Aging Population on Demand for Growth Factors in Age-Related Therapies
Personalized Medicine and Its Influence on Growth Factors Market Trends
Here's the Story on Growth Factors in Neurological Repair and Regeneration
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Growth Factors (Blood and Tissue) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: USA 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: Canada 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
JAPAN
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: Japan 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
CHINA
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: China Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: China 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
EUROPE
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Europe 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Europe 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
FRANCE
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: France Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: France 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
GERMANY
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Germany 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Italy 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
UNITED KINGDOM
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: UK Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: UK 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Spain 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Russia 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Rest of Europe 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Asia-Pacific 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Asia-Pacific 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
AUSTRALIA
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Australia 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
INDIA
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: India Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: India 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: South Korea 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
LATIN AMERICA
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Latin America 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Latin America 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Argentina 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Brazil 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Mexico 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Latin America 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
MIDDLE EAST
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Middle East 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Middle East 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Iran 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Israel 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Saudi Arabia 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: UAE 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Rest of Middle East 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030
AFRICA
Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Africa 15-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2015, 2025 & 2030